2005-11-10 M Nicklasson 1

The AstraZeneca Site in the Göteborg Region The AstraZeneca Site in the Göteborg Region The Headquarter for Cardiovascular and The Headquarter for Cardiovascular and

Gastrointestinal ResearchGastrointestinal Research

Martin NicklassonMartin NicklassonExecutive Vice President, AstraZeneca plcExecutive Vice President, AstraZeneca plc

CEO & President, AstraZeneca ABCEO & President, AstraZeneca AB

2005-11-10 M Nicklasson 2

AstraZeneca in SwedenKey figures

Sales in Sweden 2 billion SEK

– percent of Group sales 1.4%

– including parallel import 2.9 billion SEK

Market share 8.4%

Rank in Swedish pharmaceutical market No. 2

Swedish export 39 billion SEK

Share of Swedish net export 20%

Swedish licensing income 8 billion SEK

No. of Swedish shareholders 161,000

Share of Swedish ownership 22.7%

(of total No. of shares)

2005-11-10 M Nicklasson 3

Mölndal

2005-11-10 M Nicklasson 4

R&D units

Montreal Södertälje

Boston

CharnwoodAlderley

Lund

Mölndal

OsakaWilmington

Reims BrisbaneBangalore

2005-11-10 M Nicklasson 5

AZ Cardiovascular Drug DiscoveryResearch Areas at the Mölndal site

• Metabolism:• Obesity• Dyslipidemia• Diabetes

• Atherosclerosis

• Thromboembolism

• Cardiology

2005-11-10 M Nicklasson 6

AZ Gastrointestinal Drug Discovery Research Areas at the Mölndal site

• Gastroesophageal Erosive Reflux Disease

• Functional Gastrointestinal Disorders

• Inflammatory Bowel Disease

2005-11-10 M Nicklasson 7

Key factors driving collaborations

• Access to broader basic knowledge as base for new projects or specific competence for key technologies

• Create networks to increase the recruitment base

• Access to unique expertise that can’t or shouldn’t be built in-house

• Facilitate establishment of high quality research groups within areas of long term strategic importance

2005-11-10 M Nicklasson 8

Elements of innovation in Drug Discovery at AstraZeneca

1. Presence in a global network of research sites on major continents within AstraZeneca

2. Effective in-house drug discovery and research informaticsprocesses (knowledge transfer)

3. Mechanisms for learning (adoptation of best practices)

4. Network of important academic and biotechnology partners

5. Effective management of research at several sites and continents

2005-11-10 M Nicklasson 9

How important are the links to academic research in the Gothenburg region?

• Current AstraZeneca collaboration value to Gothenburg University amounts to a total of 7.34 m$

• The relations with Academia have in the past contributed to significant discoveries (Losec®, Nexium®, Seloken®)

2005-11-10 M Nicklasson 10

Areas of collaboration in drug develop-ment – AstraZeneca and Gothenburg University

Epidemiology – ”get to know the disease”

Mechanistical research – ”get to know how to test Proof of Principle for a new substance”

Large scale clinical trials – landmark studies with potential to change routine therapy

General consultancy – expert advice at any stage of drug development

2005-11-10 M Nicklasson 11

Specific examples of collaboration

Epidemiology

Hypertension, myocardial infarction, heart failure

Metabolic diseases– Diabetes– Obesity

Acid secretion related to GI diseases

2005-11-10 M Nicklasson 12

Specific examples of collaboration

Mechanistical research

GI laboratory

Metabolic laboratory

Cardiovascular clinical physiology laboratory

Arrhythmia laboratory

Development of sophisticated techniques to measure treatment effects

2005-11-10 M Nicklasson 13

Specific examples of collaborationLarge scale clinical trials

Hypertension (e.g. HAPPHY, MAPHY, HOT)

Heart failure (e.g. MERIT, CHARM)

Myocardial infarction (GMT, MIAMI)

Lipid disorders (CORONA)

Thrombosis related disorders (METHRO)

Acid secretion related GI disorders

University scientists in Scientific Steering Committees. Results of studies which have (or will) shift treatment guidelines for the disease.

2005-11-10 M Nicklasson 14

Industry – academia collaboration

Prerequisites– Scientists on both sides work together with Trust and

Respect

This requires– Same competence level– Personal chemistry OK– Genuine wish to collaborate

N.B.– Need to be in frontline of research on a worldwide basis– Industry needs to seek collaboration with “the best” to be

competitive

2005-11-10 M Nicklasson 15

Key factors for AstraZeneca’s continued presence in the region

AstraZeneca captures biomedical innovations globally through its research presence at different continents.

Critical for the locations in Gothenburg is:• The proximity to and the ability of the local universities to develop world class basic bio- medical and chemical research

• The ability of the universities to educate high quality students

• To make clear and public statements in important ethical issues, such as:

- Positive attitude and support to animal experimentation

- Stem cell research

• Providing for excellent infrastructure facilities employment of scientists coming from abroad:

- International schools of high quality

The focus of the region to applied/translational research is for AstraZeneca of lesser

importance

2005-11-10 M Nicklasson 16

Conclusions

• Academia and Biotech collaborations play and will play a very

important part in AstraZeneca

• Academia research will always be a major source of innovation for pharma industry

• True partnership can only thrive when there is a natural interest between scientists

Technology integration

New Drug Project generation